Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

    Cancer Categories
    • Breast,Genitourinary (GU),Gynecologic,Lung,Skin
    Karmanos Trial ID
    • 2020-002
    NCT ID
    • NCT04158336
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator

    Objective:

    Phase 1 Primary Objective: To investigate the safety and tolerability of single agent ZN-c3, including identification of the MTD/RP2D
    Secondary Objectives:
    1. To obtain preliminary estimates of antitumor efficacy of single agent ZN-c3
    2. To investigate the PK of single agent ZN-c3
    Exploratory: To investigate the pharmacodynamics of single agent ZN-c3

    Phase 2: Primary Objectives:
    1. To investigate the antitumor efficacy (objective response rate [ORR]) of ZN-c3 as a single agent and in combination with talazoparib and with pembrolizumab, respectively
    2. To investigate the safety of ZN-c3 as a single agent and in combination with talazoparib and with pembrolizumab,respectively, including the determination of a RP2D for the combinations

    Phase 2: Secondary Objectives:
    1. To further investigate the antitumor efficacy (duration of response [DOR], clinical benefit rate [CBR], progression-free survival [PFS]) of ZN-c3 as a single agent and in combination with talazoparib and with pembrolizumab, respectively
    2. To further determine the PK parameters of ZN-c3 and the combination drugs, as applicable

    Phase 2: Exploratory Objective: To investigate the pharmacodynamics of single agent ZN-c3 and in combination with talazoparib and with pembrolizumab, respectively.
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266